A novel AllGlo probe-quantitative PCR method for detecting single nucleotide polymorphism in CYP2C19 to evaluate the antiplatelet activity of clopidogrel

Hongwei Li,Yizhen Fang,Yongquan Chen,Yuning Lin,Zanxi Fang,Zhiyuan Lin,Huabin Xie,Zhongying Zhang

DOI: https://doi.org/10.1038/s41598-024-52540-3

IF: 4.6

2024-01-30

Scientific Reports

Abstract:CYP2C19 gene has multiple single nucleotide polymorphism (SNP), which is the major determinant for clopidogrel treatment responses. Therefore, CYP2C19 SNP detection is essential for predicting clopidogrel efficacy. Currently, there is still no quick and effective method for routine detection of common CYP2C19 SNPs in clinical laboratories, which is critically needed prior to clopidogrel treatment. AllGloTM based quantitative PCR was used to develop a novel genotyping method for CYP2C19 SNP detection, termed CyPAllGlo. The performance of CyPAllGlo was compared with that of the commonly used fluorescence in situ hybridization (FISH) method, and the data was verified by DNA sequencing. CyPallGlo was used to identify CYP2C19 polymorphisms in 363 patients with coronary heart disease. The univariate analysis was used to access the antiplatelet efficacy of clopidogrel in patients. The associations between CYP2C19 polymorphisms and clopidogrel efficacy were analyzed. Using CyPAllGlo to detect CYP2C19*2 and CYP2C19*3 alleles was highly specific and fast. The detection limit was approximately 0.07 μg/μl and 0.7 μg/μl for CYP2C19*2 and CYP2C19*3, respectively. The consistency between FISH and CyPAllGlo were 98.07% for CYP2C19*2 and 99.17% for CYP2C19*3. DNA sequencing showed that the accuracy of CyPAllGlo was 100%. The analysis time for the whole CyPAllGlo procedure was approximately 60 min. Univariate analysis showed that the anticoagulation efficacy of clopidogrel was related to patient age, CYP2C19 genotype, metabolic phenotype, and LDL level. The logistic regression analysis showed that the genotype of CYP2C19 and metabolic phenotype was the two risk factors for clopidogrel antiplatelet ineffectiveness. This novel CyPAllGlo is a rapid and accurate method for detection of CYP2C19 SNP. The specificity and consistency of CyPAllGlo are comparable with that of widely used DNA sequencing. These findings provide valuable rapid method for predicting clopidogrel efficacy, which can be quickly translated to improve personalized precision medicine for coronary heart disease treatment.

multidisciplinary sciences

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop a fast, efficient and accurate method to detect single - nucleotide polymorphisms (SNPs) in the CYP2C19 gene, especially the two common SNPs, CYP2C19*2 and CYP2C19*3. The enzyme encoded by the CYP2C19 gene plays a crucial role in the metabolism of clopidogrel, and polymorphisms in the CYP2C19 gene can affect the therapeutic effect of clopidogrel. Therefore, detecting CYP2C19 SNPs is essential for predicting the efficacy of clopidogrel.

Currently, there is a lack of rapid and effective routine detection methods in clinical laboratories to detect common CYP2C19 SNPs, which are highly needed before clopidogrel treatment. For this purpose, researchers have developed a new quantitative PCR method named CyPAllGlo for the detection of CYP2C19 SNPs using AllGlo™ technology, and compared its performance with the commonly used fluorescence in - situ hybridization (FISH) method. The data were verified by DNA sequencing. The research results show that CyPAllGlo is a fast and accurate method for detecting CYP2C19 SNPs, and its specificity and consistency are comparable to the widely - used DNA sequencing. These findings provide a valuable and rapid method for predicting the efficacy of clopidogrel and can be quickly transformed into a tool for improving personalized and precise medicine for coronary heart disease.